الفهرس 
Corona VirusOnly 14 pages are availabe for public view
 |  | from | 132 |  |  |
| | | from | 132 | | |
Abstract
Background: SARS-COV-2 (Coronavirus Disease-2019) is a disease caused by the coronavirus. SARS-CoV-2 (Sever Acute Respiratory Syndrome-Coronavirus-2) has emerged as a rapidly spreading pandemic with more than 6 million deaths.
Aim of the Work: To illuminate to what extent metabolic syndrome can be used as a prognostic factor for the outcomes of patients infected with SARS-COV-2. Primary outcome measures the ICU stay and outcome. Secondary outcome measures are patients requiring Mechanical ventilation (MV) and mortality.
Patients and Methods: This was a retrospective study which included 90 patients admitted to ICU for Pneumonic COVID-19 with a confirmed positive RT-PCR for COVID-19 and chest computed tomography. They were divided into two groups according to presence or absent of metabolic syndrome
Results: Patients with metabolic syndrome have significantly higher liver transaminases, serum creatinine, random blood glucose, triglycerides and markers of acute phase reactant (Ferritin and LDH) and P/F ratio compared to those without metabolic syndrome(p<0.05). Components of metabolic syndrome such as hypertension, type 2 diabetes mellitus (T2DM), and obesity significantly increase the risk of hospitalization and mortality in SARS-COV-2 patients (p<0.05).
Conclusion: Metabolic syndrome (MetS) is a better prognostic indicator for severe disease outcomes in patients with COVID-19 than its individual components. Patients with MetS had a significantly higher need for ICU admission irrespective of their age, sex, or race. The need for mechanical ventilation was also higher across all patients with MetS. The association of MetS with higher mortality was significant for females, patients younger than 65 years of age.